Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.45
PRXL's Cash-to-Debt is ranked lower than
75% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. PRXL: 0.45 )
Ranked among companies with meaningful Cash-to-Debt only.
PRXL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.35  Med: 4.08 Max: 336.54
Current: 0.45
0.35
336.54
Equity-to-Asset 0.27
PRXL's Equity-to-Asset is ranked lower than
87% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. PRXL: 0.27 )
Ranked among companies with meaningful Equity-to-Asset only.
PRXL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.45 Max: 0.64
Current: 0.27
0.27
0.64
Debt-to-Equity 1.06
PRXL's Debt-to-Equity is ranked lower than
86% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. PRXL: 1.06 )
Ranked among companies with meaningful Debt-to-Equity only.
PRXL' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.08 Max: 1.06
Current: 1.06
0
1.06
Debt-to-EBITDA 2.26
PRXL's Debt-to-EBITDA is ranked lower than
56% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. PRXL: 2.26 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PRXL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.48  Med: 1.56 Max: 2.26
Current: 2.26
0.48
2.26
Interest Coverage 15.54
PRXL's Interest Coverage is ranked lower than
59% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. PRXL: 15.54 )
Ranked among companies with meaningful Interest Coverage only.
PRXL' s Interest Coverage Range Over the Past 10 Years
Min: 3.16  Med: 9.74 Max: 28.15
Current: 15.54
3.16
28.15
Piotroski F-Score: 5
Altman Z-Score: 3.56
Beneish M-Score: -2.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 7.83
PRXL's Operating Margin % is ranked higher than
65% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. PRXL: 7.83 )
Ranked among companies with meaningful Operating Margin % only.
PRXL' s Operating Margin % Range Over the Past 10 Years
Min: 5.49  Med: 7.14 Max: 9.23
Current: 7.83
5.49
9.23
Net Margin % 4.39
PRXL's Net Margin % is ranked higher than
64% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. PRXL: 4.39 )
Ranked among companies with meaningful Net Margin % only.
PRXL' s Net Margin % Range Over the Past 10 Years
Min: 3.11  Med: 4.6 Max: 6.38
Current: 4.39
3.11
6.38
ROE % 17.53
PRXL's ROE % is ranked higher than
86% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. PRXL: 17.53 )
Ranked among companies with meaningful ROE % only.
PRXL' s ROE % Range Over the Past 10 Years
Min: 9.33  Med: 16.82 Max: 23.85
Current: 17.53
9.33
23.85
ROA % 4.92
PRXL's ROA % is ranked higher than
72% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. PRXL: 4.92 )
Ranked among companies with meaningful ROA % only.
PRXL' s ROA % Range Over the Past 10 Years
Min: 3.4  Med: 5.37 Max: 7.99
Current: 4.92
3.4
7.99
ROC (Joel Greenblatt) % 44.94
PRXL's ROC (Joel Greenblatt) % is ranked higher than
81% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. PRXL: 44.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PRXL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 21.14  Med: 41.97 Max: 58.04
Current: 44.94
21.14
58.04
3-Year Revenue Growth Rate 5.90
PRXL's 3-Year Revenue Growth Rate is ranked higher than
54% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. PRXL: 5.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PRXL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.3  Med: 14.6 Max: 39.5
Current: 5.9
5.3
39.5
3-Year EBITDA Growth Rate 5.30
PRXL's 3-Year EBITDA Growth Rate is ranked lower than
53% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. PRXL: 5.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PRXL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -11.3  Med: 14.2 Max: 56.4
Current: 5.3
-11.3
56.4
3-Year EPS without NRI Growth Rate -2.90
PRXL's 3-Year EPS without NRI Growth Rate is ranked lower than
53% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. PRXL: -2.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PRXL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -32.8  Med: 16.7 Max: 40.6
Current: -2.9
-32.8
40.6
GuruFocus has detected 5 Warning Signs with Parexel International Corp PRXL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PRXL's 30-Y Financials

Financials (Next Earnings Date: 2018-02-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

PRXL Guru Trades in Q4 2016

Paul Tudor Jones 82,309 sh (New)
Jana Partners 745,665 sh (New)
Joel Greenblatt 120,706 sh (+86.44%)
Steven Cohen Sold Out
Ken Fisher 2,244,444 sh (-2.92%)
Vanguard Health Care Fund 1,108,785 sh (-5.11%)
Chuck Royce 239,400 sh (-18.46%)
» More
Q1 2017

PRXL Guru Trades in Q1 2017

Vanguard Health Care Fund 1,108,785 sh (unchged)
Jana Partners Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 2,160,308 sh (-3.75%)
Chuck Royce 148,000 sh (-38.18%)
» More
Q2 2017

PRXL Guru Trades in Q2 2017

Mario Gabelli 11,450 sh (New)
Paul Tudor Jones 92,070 sh (New)
Joel Greenblatt 154,363 sh (New)
Chuck Royce Sold Out
Vanguard Health Care Fund Sold Out
Ken Fisher 2,114,547 sh (-2.12%)
» More
Q3 2017

PRXL Guru Trades in Q3 2017

Caxton Associates 4,200 sh (New)
Lee Ainslie 56,180 sh (New)
Paul Tudor Jones Sold Out
Ken Fisher Sold Out
Mario Gabelli 10,540 sh (-7.95%)
Joel Greenblatt 54,850 sh (-64.47%)
» More
» Details

Insider Trades

Latest Guru Trades with PRXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 Reduce -64.47%0.12%$86.94 - $88.1 $ 88.081%54,850
Mario Gabelli 2017-09-30 Reduce -7.95%$86.94 - $88.1 $ 88.081%10,540
Ken Fisher 2017-09-30 Sold Out 0.29%$86.94 - $88.1 $ 88.081%0
Ken Fisher 2017-06-30 Reduce -2.12%$61.1 - $87.25 $ 88.0819%2,114,547
Joel Greenblatt 2017-06-30 New Buy0.19%$61.1 - $87.25 $ 88.0819%154,363
Mario Gabelli 2017-06-30 New Buy0.01%$61.1 - $87.25 $ 88.0819%11,450
Vanguard Health Care Fund 2017-06-30 Sold Out 0.16%$61.1 - $87.25 $ 88.0819%0
Ken Fisher 2017-03-31 Reduce -3.75%0.01%$61.25 - $71.44 $ 88.0833%2,160,308
Joel Greenblatt 2017-03-31 Sold Out 0.1%$61.25 - $71.44 $ 88.0833%0
Ken Fisher 2016-12-31 Reduce -2.92%0.01%$55.73 - $70.4 $ 88.0840%2,244,444
Vanguard Health Care Fund 2016-12-31 Reduce -5.11%0.01%$55.73 - $70.4 $ 88.0840%1,108,785
Joel Greenblatt 2016-12-31 Add 86.44%0.05%$55.73 - $70.4 $ 88.0840%120,706
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541711    SIC: 8731
Compare:NYSE:ALR, NAS:VWR, XTER:AFX, NAS:BRKR, MIL:DIA, NAS:DXCM, NAS:PRAH, NYSE:CRL, SHSE:603658, NAS:NEOG, NAS:INCR, NAS:EXAS, BSP:FLRY3, TSE:4544, XTER:SRT3, BSP:DASA3, NAS:ICLR, NAS:MYGN, NYSE:BIO, SZSE:300244 » details
Traded in other countries:PAX.Germany,
Headquarter Location:USA
Parexel International Corp is a biopharmaceutical services company. It offers clinical research, clinical logistics, medical communications, and technology products and services to the pharmaceutical, biotechnology, and medical device industries.

Parexel is a global contract research organization that provides outsourced research and development services to pharmaceutical and biotechnology companies. Although the firm's clinical research services segment brings in the lion's share of revenue, Parexel also offers technical expertise and advice through its consulting and medical communications services segment, as well as information technology solutions through its Perceptive Informatics segment.

Ratios

vs
industry
vs
history
PE Ratio 42.97
PRXL's PE Ratio is ranked lower than
63% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. PRXL: 42.97 )
Ranked among companies with meaningful PE Ratio only.
PRXL' s PE Ratio Range Over the Past 10 Years
Min: 6.5  Med: 26.06 Max: 42.98
Current: 42.97
6.5
42.98
Forward PE Ratio 22.27
PRXL's Forward PE Ratio is ranked higher than
58% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.26 vs. PRXL: 22.27 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 42.97
PRXL's PE Ratio without NRI is ranked lower than
62% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.88 vs. PRXL: 42.97 )
Ranked among companies with meaningful PE Ratio without NRI only.
PRXL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.5  Med: 26.03 Max: 42.98
Current: 42.97
6.5
42.98
Price-to-Owner-Earnings 24.02
PRXL's Price-to-Owner-Earnings is ranked higher than
68% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. PRXL: 24.02 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PRXL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.73  Med: 22.5 Max: 256.94
Current: 24.02
9.73
256.94
PB Ratio 7.09
PRXL's PB Ratio is ranked lower than
79% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. PRXL: 7.09 )
Ranked among companies with meaningful PB Ratio only.
PRXL' s PB Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.66 Max: 8
Current: 7.09
0.98
8
PS Ratio 1.88
PRXL's PS Ratio is ranked higher than
75% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. PRXL: 1.88 )
Ranked among companies with meaningful PS Ratio only.
PRXL' s PS Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.25 Max: 1.88
Current: 1.88
0.33
1.88
Price-to-Free-Cash-Flow 19.53
PRXL's Price-to-Free-Cash-Flow is ranked higher than
66% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. PRXL: 19.53 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PRXL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.42  Med: 19.26 Max: 127.89
Current: 19.53
9.42
127.89
Price-to-Operating-Cash-Flow 14.92
PRXL's Price-to-Operating-Cash-Flow is ranked higher than
67% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. PRXL: 14.92 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PRXL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.13  Med: 13.24 Max: 132.14
Current: 14.92
5.13
132.14
EV-to-EBIT 25.48
PRXL's EV-to-EBIT is ranked higher than
56% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. PRXL: 25.48 )
Ranked among companies with meaningful EV-to-EBIT only.
PRXL' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.9  Med: 17.5 Max: 25.48
Current: 25.48
5.9
25.48
EV-to-EBITDA 16.37
PRXL's EV-to-EBITDA is ranked higher than
61% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. PRXL: 16.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRXL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 11.2 Max: 16.37
Current: 16.37
4.3
16.37
EV-to-Revenue 2.00
PRXL's EV-to-Revenue is ranked higher than
78% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. PRXL: 2.00 )
Ranked among companies with meaningful EV-to-Revenue only.
PRXL' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 1.25 Max: 2
Current: 2
0.5
2
PEG Ratio 2.49
PRXL's PEG Ratio is ranked higher than
59% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.98 vs. PRXL: 2.49 )
Ranked among companies with meaningful PEG Ratio only.
PRXL' s PEG Ratio Range Over the Past 10 Years
Min: 0.24  Med: 1.39 Max: 15.37
Current: 2.49
0.24
15.37
Shiller PE Ratio 52.65
PRXL's Shiller PE Ratio is ranked lower than
60% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 49.53 vs. PRXL: 52.65 )
Ranked among companies with meaningful Shiller PE Ratio only.
PRXL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.29  Med: 52.69 Max: 124
Current: 52.65
23.29
124
Current Ratio 1.45
PRXL's Current Ratio is ranked lower than
77% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. PRXL: 1.45 )
Ranked among companies with meaningful Current Ratio only.
PRXL' s Current Ratio Range Over the Past 10 Years
Min: 1.34  Med: 1.6 Max: 2.36
Current: 1.45
1.34
2.36
Quick Ratio 1.45
PRXL's Quick Ratio is ranked lower than
68% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. PRXL: 1.45 )
Ranked among companies with meaningful Quick Ratio only.
PRXL' s Quick Ratio Range Over the Past 10 Years
Min: 1.34  Med: 1.6 Max: 2.36
Current: 1.45
1.34
2.36
Days Sales Outstanding 87.93
PRXL's Days Sales Outstanding is ranked lower than
67% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. PRXL: 87.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRXL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.59  Med: 84.65 Max: 149.34
Current: 87.93
61.59
149.34
Days Payable 22.01
PRXL's Days Payable is ranked lower than
85% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. PRXL: 22.01 )
Ranked among companies with meaningful Days Payable only.
PRXL' s Days Payable Range Over the Past 10 Years
Min: 9.9  Med: 13.54 Max: 22.01
Current: 22.01
9.9
22.01

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.20
PRXL's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. PRXL: 2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRXL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -21.2  Med: -1.35 Max: 2.8
Current: 2.2
-21.2
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.56
PRXL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
66% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. PRXL: 1.56 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PRXL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.54  Med: 2.42 Max: 7.33
Current: 1.56
1.54
7.33
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.94
PRXL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
50% of the 18 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. PRXL: 1.94 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
PRXL' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.82  Med: 2.26 Max: 2.93
Current: 1.94
0.82
2.93
Price-to-Median-PS-Value 1.51
PRXL's Price-to-Median-PS-Value is ranked lower than
76% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. PRXL: 1.51 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PRXL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.47  Med: 0.93 Max: 2.68
Current: 1.51
0.47
2.68
Price-to-Peter-Lynch-Fair-Value 2.38
PRXL's Price-to-Peter-Lynch-Fair-Value is ranked lower than
52% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. PRXL: 2.38 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
PRXL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.85  Med: 1.89 Max: 5.07
Current: 2.38
0.85
5.07
Earnings Yield (Greenblatt) % 3.92
PRXL's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. PRXL: 3.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PRXL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.9  Med: 5.7 Max: 16.9
Current: 3.92
3.9
16.9
Forward Rate of Return (Yacktman) % 21.35
PRXL's Forward Rate of Return (Yacktman) % is ranked higher than
83% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. PRXL: 21.35 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PRXL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.8  Med: 21.4 Max: 33.7
Current: 21.35
3.8
33.7

More Statistics

Revenue (TTM) (Mil) $2,441.50
EPS (TTM) $ 2.05
Short Percentage of Float2.24%
52-Week Range $51.16 - 88.10
Shares Outstanding (Mil)51.12

Analyst Estimate

Jun18 Jun19
Revenue (Mil $) 2,210 2,358
EPS ($) 3.96 4.81
EPS without NRI ($) 3.96 4.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.06%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}